ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.
Open access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches.Medical oncology (Northwood, London, England) · 2025Review
- Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies.ESMO gastrointestinal oncology · 2025Review
- Article
- BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Nature reviews. Clinical oncology · 2024Review
- Biomimetic Synthesis and Chemical Proteomics Reveal the Mechanism of Action and Functional Targets of Phloroglucinol Meroterpenoids.Journal of the American Chemical Society · 2024Article
- A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma.Cell death & disease · 2023Article
- Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.Molecular biomedicine · 2022Review
- Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.Investigational new drugs · 2022Article
- Article
- Review
- Review
- [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant Advanced Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- Targeting Autophagy with Natural Products as a Potential Therapeutic Approach for Cancer.International journal of molecular sciences · 2021Review
- ERK Inhibitor LY3214996-Based Treatment Strategies forMolecular cancer therapeutics · 2021Article
- Computational high-throughput screening andOncology research · 2021Article
- PI3K inhibitors: review and new strategies.Chemical science · 2020Review
- Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.American journal of cancer research · 2020Article
- Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours.Journal of oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 1 country.
Clinton YamAbramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Xiaowei XuAbramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Michael A DaviesThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Phyllis A GimottyDepartment of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Jennifer J D MorrissetteCenter for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Michael T TetzlaffThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Khalida M WaniThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Shujing LiuAbramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Wanleng DengThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Meghan BuckleyDepartment of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Jianhua ZhaoCenter for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Ravi K AmaravadiAbramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Naomi B HaasAbramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Ragini R KudchadkarH. Lee Moffitt Cancer Center, Tampa, Florida.
Anna C PavlickNew York University Medical Center, New York, New York.
Jeffrey A SosmanVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Hussein TawbiThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Luke WalkerCascadian Therapeutics (formerly Oncothyreon) Inc., Seattle, Washington.
Lynn M SchuchterAbramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Giorgos C KarakousisAbramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Tara C GangadharAbramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. tara.gangadhar@uphs.upenn.edu.
The University of Texas MD Anderson Cancer Center · USMoffitt Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MThe role of the PI3K pathway in immune resistanceR01CA187076 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL, HWU, PATRICK · 2014 to 2018
$2.0MThe Role of the PI3K-AKT Pathway in Melanoma Brain MetastasisR01CA154710 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2011 to 2015
$1.6MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA154710NCI NIH HHS R01 CA187076NCI NIH HHS T32 CA009666
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationPhosphoinositide-3 Kinase InhibitorsAdultAgedAllelesAntineoplastic Combined Chemotherapy ProtocolsFemaleGonanesHumansMaleMiddle AgedNeoplasm MetastasisNeoplasmsNeoplasm StagingProto-Oncogene Proteins B-rafSignal TransductionGonanesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins B-rafPX-866Vemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.